Company news
Cue Biopharma, Inc. (NASDAQ:CUE) news
Every Cue Biopharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
September 20, 2026
Currency Exchange International : Reports a 24% Increase in its Third Quarter Gro...
September 9, 2026
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
August 3, 2026
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
July 13, 2026
Cue Biopharma Announces $50.0 Million Private Placement
July 8, 2026
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
June 2, 2026
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
May 21, 2026
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
May 14, 2026
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Cue Biopharma Announces $30 Million Private Placement
April 30, 2026
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
April 30, 2026
Cue Biopharma Announces 1-for-30 Reverse Stock Split
April 22, 2026
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
April 15, 2026
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
April 8, 2026
Cue Biopharma Announces CEO Transition
March 27, 2026
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
March 26, 2026
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
March 16, 2026
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
March 9, 2026
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
February 17, 2026
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
February 12, 2026
Cue Biopharma Announces Pricing of $10 Million Public Offering
December 19, 2025
Cue Biopharma Announces Proposed Public Offering
December 18, 2025
Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
November 6, 2025
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
September 29, 2025
Cue Biopharma to Participate in Fireside Chat at the Cantor Global Healthcare Conference
August 21, 2025
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
August 13, 2025
Cue Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
August 12, 2025
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer
July 16, 2025
Cue Biopharma Provides Update on Most Advanced Clinical Stage Asset, CUE-101, Presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit on Thoracic Malignancies
July 1, 2025
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
June 24, 2025
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
May 12, 2025
Cue Biopharma to Host Virtual Investor Event on May 15, 2025
May 8, 2025
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
May 5, 2025
Cue Biopharma to Host Business Update Call and Webcast
April 14, 2025
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
April 14, 2025
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
April 13, 2025
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
March 31, 2025
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
Cue Biopharma Announces Strategic Organizational Transition
November 14, 2024
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
November 8, 2024
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 4, 2024
Cue Biopharma Announces Proposed Public Offering
September 26, 2024
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
September 26, 2024
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
September 9, 2024
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 19, 2024
Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements
July 25, 2024
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
June 4, 2024
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
June 3, 2024